Eterus Capital and Ethernum Capital have partnered to consolidate the Slovak pharmacy market
Eterus Capital has acquired a majority stake in EC Pharmacies, a consolidation platform established in partnership with Ethernum Capital.
Eterus Capital is a private equity fund founded in 2008, specializing in supporting small and medium-sized enterprises with proven business models and growth potential. The fund focuses on minority investments, ensuring management control remains with the original shareholders. Over the years, Eterus Capital has provided more than US$41 million (€40 million) in funding to over 20 companies. Its portfolio includes prominent brands such as Sygic, HOPIN, eyerim, Saneca Pharmaceuticals, Groupsolver and MTBIKER.
EC Pharmacies is a joint venture between Eterus Capital and Ethernum Capital, established to consolidate the Slovak pharmacy market through a "buy-and-build" strategy. The objective is to acquire 25–50 targeted pharmacies, improve operational performance, centralize marketing and supply chains and ultimately sell the established network to a strategic partner. Since its inception, EC Pharmacies has acquired nine pharmacies with an estimated annual portfolio revenue of US$6.2 million (€6 million). The company plans to expand its network by launching and acquiring additional operations in the near future, further strengthening its market presence.
Oaklins’ team in Slovakia advised the buyer in this transaction.
Talk to the deal team
Related deals
Valmiermuižas Alus has been acquired by Cēsu Alus
Valmiermuižas Alus has been acquired by Cēsu Alus AS through the purchase of 100% of its shares. The transaction enabled the founder’s exit and strengthened the company’s platform for continued growth within a consolidating Baltic beverage market.
Learn moreLindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreArmira has signed an agreement to acquire a majority stake in Viabus
Armira, a Germany-based investment firm, has signed an agreement to acquire a majority stake in Viabus, a leading Dutch tour operator focused on senior and young senior travelers.
Learn more